Literature DB >> 15452062

Effect of latanoprost on intraocular pressure in mice lacking the prostaglandin FP receptor.

Jonathan G Crowston1, James D Lindsey, Makoto Aihara, Robert N Weinreb.   

Abstract

PURPOSE: To determine whether latanoprost lowers IOP in prostaglandin FP receptor knockout mice.
METHODS: Mean IOP difference between treated and untreated fellow eyes was measured on three separate occasions, 2 hours after a 200-ng dose of latanoprost to the right eye of homozygous (n = 9) and heterozygous (n = 15) FP knockout mice. C57BL/6 (n = 10) and NIH Swiss white mice (n = 17), which have normal FP receptor expression, provided the control population. The investigator was masked to the genotype of the FP knockout mice at the time of IOP measurement.
RESULTS: Latanoprost had no effect on IOP in the homozygous FP knockout mice, with an average difference in IOP between treated and untreated fellow eyes of +0.25 mm Hg and a 95% confidence interval (CI) for the difference between means of -0.019 to +0.69. In contrast, latanoprost reduced IOP in the treated eye of the heterozygous FP knockout, C57BL/6, and Swiss white mice with mean differences and 95% CI of the difference in means of -0.52 (-0.91 to -0.14), -1.38 (-2.1 to -0.70), and -1.29 (-1.78 to -0.79) mm Hg, respectively.
CONCLUSIONS: FP receptor signaling plays a crucial role in the early IOP response to latanoprost in the mouse eye.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452062     DOI: 10.1167/iovs.04-0338

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  10 in total

1.  Pharmacologic manipulation of conventional outflow facility in ex vivo mouse eyes.

Authors:  Alexandra Boussommier-Calleja; Jacques Bertrand; David F Woodward; C Ross Ethier; W Daniel Stamer; Darryl R Overby
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-08-24       Impact factor: 4.799

2.  The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice.

Authors:  Takashi Ota; Makoto Aihara; Tadashiro Saeki; Shuh Narumiya; Makoto Araie
Journal:  Br J Ophthalmol       Date:  2006-11-23       Impact factor: 4.638

3.  Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility.

Authors:  Gavin W Roddy; Uttio Roy Chowdhury; Kjersten J Anderson; Tommy A Rinkoski; Cheryl R Hann; Vince A Chiodo; W Clay Smith; Michael P Fautsch
Journal:  PLoS One       Date:  2022-05-31       Impact factor: 3.752

4.  Travoprost in the management of open-angle glaucoma and ocular hypertension.

Authors:  Philippe Denis; David Covert; Anthony Realini
Journal:  Clin Ophthalmol       Date:  2007-03

5.  Enhanced inflow and outflow rates despite lower IOP in bestrophin-2-deficient mice.

Authors:  Youwen Zhang; Bryan R Davidson; W Daniel Stamer; Jennifer K Barton; Lihua Y Marmorstein; Alan D Marmorstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-20       Impact factor: 4.799

Review 6.  The Suprachoroidal Route in Glaucoma Surgery.

Authors:  Anthony Gigon; Tarek Shaarawy
Journal:  J Curr Glaucoma Pract       Date:  2016-05-12

Review 7.  The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies.

Authors:  Megan E Cavet; Heleen H DeCory
Journal:  J Ocul Pharmacol Ther       Date:  2017-08-07       Impact factor: 2.671

8.  The Roles Played by FP/EP3 Receptors During Pressure-lowering in Mouse Eyes Mediated by a Dual FP/EP3 Receptor Agonist.

Authors:  Reiko Yamagishi-Kimura; Megumi Honjo; Makoto Aihara
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-02-01       Impact factor: 4.799

9.  A model for the easy assessment of pressure-dependent damage to retinal ganglion cells using cyan fluorescent protein-expressing transgenic mice.

Authors:  Hidekazu Tsuruga; Hiroshi Murata; Makoto Araie; Makoto Aihara
Journal:  Mol Vis       Date:  2012-10-05       Impact factor: 2.367

10.  Contribution of prostanoid FP receptor and prostaglandins in transient inflammatory ocular hypertension.

Authors:  Reiko Yamagishi-Kimura; Megumi Honjo; Makoto Aihara
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.